Early-Stage Biotechs Feel the Squeeze as Funding Favors Derisked Assets: JPM

Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P. Morgan found in a report published ahead of the bank’s annual healthcare conference in San Francisco.